Peptide research news

A new SURPASS CVOT analysis compares tirzepatide and dulaglutide in diabetes patients with heart disease.

FDA expanded approval of nogapendekin alfa inbakicept combined with BCG to more bladder cancer patients, per an FDA drug announcement.

A new analysis looks at how quickly patients started oral semaglutide for obesity once it reached pharmacies.

An injectable compound called CBL-514 triggered fat cell death and shrank visceral fat in phase 2 trials, researchers reported.

A new review in J Endocr Soc examines whether GLP-1 receptor agonists raise the risk of a rare optic nerve condition.

A new analysis looks at pregnancy outcomes in women exposed to the migraine drug galcanezumab during trials and after approval.

FDA approved pritelivir, a new antiviral for immunocompromised patients with herpes lesions unresponsive to standard treatments.

FDA approved atezolizumab with chemotherapy for Stage III dMMR colon cancer after a trial showed major disease free survival gains.

A new paper in J Diabetes Metab Disord examines cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.

Stanford researchers blocked an aging linked enzyme and regrew knee cartilage in mice, with early signs in human tissue too.

A new analysis examines weight nadirs and regain during 3 years of tirzepatide treatment in people with obesity and prediabetes.

A novel NPY2 receptor agonist called nisotirostide moves from lab discovery to early clinical testing for diabetes and obesity.

FDA approved pirtobrutinib for adults with previously untreated CLL or SLL lacking the 17p deletion, based on a randomized trial.

A retrospective pilot study looks at fat versus lean mass changes when incretin based weight loss drugs are paired with exercise and nutrition coaching.

FDA approved Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy, extending its 2022 adult approval.

A new report suggests semaglutide may lower bone marrow output of inflammatory monocytes in people with type 2 diabetes.

FDA warning letter cites Boothwyn Pharmacy for adulterated GLP1 injections, sterility failures, and mislabeled potency.

A regulatory toxicology paper examines whether current ICH guidance properly screens GLP1 receptor agonists for cancer risk.

A mouse study suggests tirzepatide, sold as Mounjaro and Zepbound, activates calorie burning brown fat beyond appetite suppression.

FDA approved Atebrioz, an oral drug that reduced new bone growth in a placebo controlled trial for FOP patients.

The FDA has approved Onswik, a once weekly long acting insulin, for adults with type 2 diabetes.

A new paper examines whether GLP1 drugs affect atrial fibrillation rates in obese HFpEF patients without diabetes.

FDA warning letter cites Empower Pharmacy for compounding tirzepatide and semaglutide products as copies of approved drugs.

A systems modeling study in a peer reviewed endocrinology journal maps how tirzepatide and semaglutide behave over time in the body.

A SURMOUNT J substudy examines how tirzepatide affects abdominal fat and metabolic markers in Japanese adults with obesity.

A small case series describes patients on tirzepatide developing repeated styes and chalazia, though a causal link remains unproven.

FDA clears Fayuvi, a one time gene therapy for pediatric MPS IIIA, based on a single arm study versus historical controls.

FDA says tirzepatide's shortage is over and clarifies when compounded GLP-1 products still qualify for legal exemptions.

FDA's new Expedited IND Pilot pairs drug sponsors with research institutions to speed early trial applications, not to approve any product.

A new mouse study looks at how chronic GIP and GLP-1 receptor activation affects the heart differently by sex and dose.

Centric Compounding recalled six lots of injectable Glutathione, Myer's Cocktail, and Tri Immune Boost after endotoxin contamination reports.

The FDA approved apitegromab, the first SMA therapy aimed directly at muscle loss rather than the underlying gene defect.

A small trial used a virtual reality buffet to study ghrelin related pharmacology in people with alcohol use disorder.

A propensity matched study looks at tirzepatide versus other GLP1 drugs in patients with inflammatory bowel disease.

FDA granted accelerated approval to sevabertinib for HER2 mutated non small cell lung cancer patients with no prior treatment.

A large Swedish cohort study found semaglutide use tied to a 21% lower psychiatric hospitalization risk in bipolar disorder.

FDA issued temporary compounding guidance to prevent a supply gap in starter IV nutrition for premature newborns.

A three patient case report looks at tirzepatide for low blood sugar after gastric bypass surgery.

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1 mutated, HR positive, HER2 negative breast cancer.

A new Pediatrics study examines how often children ages 8 to 11 with obesity are prescribed GLP-1 receptor agonists.

FDA expanded an emergency authorization so nitenpyram tablets can now prevent, not just treat, screwworm infestations in dogs and cats.

A new pharmaceutical science paper looks at how surfactants protect or fail to protect therapeutic peptides under physical stress.

FDA warning letter cites Tex Peptides for marketing semaglutide, tirzepatide and other peptides as unapproved drugs.

FDA warns that compounded and unapproved GLP1 drugs, including retatrutide and cagrilintide, carry real safety and quality risks.

An FDA panel recommended BPC-157 and TB-500 for a compounding list. That is not drug approval.

An FDA panel voted to recommend Semax for a compounding list, not to approve it as a drug.

The FDA approved Foundayo, orforglipron, the first oral GLP-1 pill with no food or water timing rules.

TRIUMPH 1, a large Phase 3 trial, found retatrutide cut body weight by up to 28.3% over 80 weeks.